Eduardo D. Espiridion
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Eduardo D. Espiridion has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Adeolu Oladunjoye
Boston Childrens Hosp, Crit Care Med, Boston, MA USA
9 shared publications - Maria Ruiza Yee
Psychiatry, Drexel University College of Medicine, Philadelphia, USA
7 shared publications Lily Charron
Psychiatry, Drexel University College of Medicine, West Reading, USA
5 shared publicationsAndrew S. Murdock
Psychiatry, Drexel University College of Medicine, Philadelphia, USA
4 shared publicationsAngelica Arshoun
Psychiatry, Drexel University College of Medicine, Reading, USA
4 shared publicationsNicole Ann E Villa
Psychiatry, Drexel University College of Medicine, Philadelphia, USA
3 shared publications
Latest Publications
- Open Access
- 7 February 2026
- Published by Springer Nature in Cureus
- Vol. 18  (2)
Mind and Muscle: A Retrospective Study on the Management of Psychiatric Comorbidities in Patients With Fibromyalgia Treated With Pregabalin Versus Milnacipran
Background: Fibromyalgia syndrome is a debilitating chronic disease with symptoms of pain and fatigue that profoundly impact patientsâ quality of life. This disability can lead to the development of psychiatric comorbidities, causing a compounding decline in overall well-being. Pregabalin and milnacipran are options for patients seeking symptomatic relief, but we hypothesized that psychiatric outcomes differ between patients with fibromyalgia treated with milnacipran versus pregabalin. Methods: TriNetX, a de-identified healthcare organization (HCO) network, collected and analyzed the study data. Patients with fibromyalgia receiving either milnacipran or pregabalin without opioid analgesics were included in this study and separated based on their use of milnacipran or pregabalin. Risk difference, risk ratios, Kaplan-Meier analysis with log-rank tests (LRTs), hazard ratios, and proportionality were analyzed for differences among several conditions: somnolence, opioid use disorder (OUD), depressive episodes (DEs), and anxiety disorder (AD) between patients on milnacipran versus pregabalin. Results: In total, 119,406 patients met the eligibility criteria, and propensity score matching resulted in 6,726 patients in each cohort. Milnacipran decreased the risk of somnolence and OUD (somnolence: 0.942%, 95% confidence interval (CI): 0.0445-1.44%, p<0.001; OUD: 0.779%, 95% CI: 0.061-1.5%, p<0.0333) (DEs: 2.1%, 95% CI: 0.3-3.89%, p=0.217; AD: 1.18%, 95% CI: -0.623-2.99%, p=0.119). Kaplan-Meier analysis demonstrated the benefit of milnacipran in the management of somnolence. There is no difference in the management of anxiety. There was a trending improvement in OUD and DE with milnacipran, but it did not show clear superiority (LRT somnolence, p<0.001; OUD, p=0.0584; DE, p=0.0504; anxiety, p=0.441). Conclusion: Overall, differences observed between groups may not be clinically significant. This information may help clinicians and patients employ well-informed, shared decision-making.
- 7 February 2026
- Published by Springer Nature in Cureus
- Vol. 18  (2)
Open AccessMind and Muscle: A Retrospective Study on the Management of Psychiatric Comorbidities in Patients With Fibromyalgia Treated With Pregabalin Versus Milnacipran
Background: Fibromyalgia syndrome is a debilitating chronic disease with symptoms of pain and fatigue that profoundly impact patientsâ quality of life. This disability can lead to the development of psychiatric comorbidities, causing a compounding decline in overall well-being. Pregabalin and milnacipran are options for patients seeking symptomatic relief, but we hypothesized that psychiatric outcomes differ between patients with fibromyalgia treated with milnacipran versus pregabalin. Methods: TriNetX, a de-identified healthcare organization (HCO) network, collected and analyzed the study data. Patients with fibromyalgia receiving either milnacipran or pregabalin without opioid analgesics were included in this study and separated based on their use of milnacipran or pregabalin. Risk difference, risk ratios, Kaplan-Meier analysis with log-rank tests (LRTs), hazard ratios, and proportionality were analyzed for differences among several conditions: somnolence, opioid use disorder (OUD), depressive episodes (DEs), and anxiety disorder (AD) between patients on milnacipran versus pregabalin. Results: In total, 119,406 patients met the eligibility criteria, and propensity score matching resulted in 6,726 patients in each cohort. Milnacipran decreased the risk of somnolence and OUD (somnolence: 0.942%, 95% confidence interval (CI): 0.0445-1.44%, p<0.001; OUD: 0.779%, 95% CI: 0.061-1.5%, p<0.0333) (DEs: 2.1%, 95% CI: 0.3-3.89%, p=0.217; AD: 1.18%, 95% CI: -0.623-2.99%, p=0.119). Kaplan-Meier analysis demonstrated the benefit of milnacipran in the management of somnolence. There is no difference in the management of anxiety. There was a trending improvement in OUD and DE with milnacipran, but it did not show clear superiority (LRT somnolence, p<0.001; OUD, p=0.0584; DE, p=0.0504; anxiety, p=0.441). Conclusion: Overall, differences observed between groups may not be clinically significant. This information may help clinicians and patients employ well-informed, shared decision-making.
- Open Access
- 16 October 2025
- Published by Springer Nature in Cureus
- Vol. 17  (10) , e94712
Demographic, Socioeconomic, and Clinical Determinants of Repeat Suicide Attempts: A Retrospective Study of Emergency Department Visits at a Community Hospital
Background: Suicide is a critical public health issue in the United States, yet research is lacking on understanding the population that visits the Emergency Department (ED) for repeated suicide attempts (SA) and self-harm (SH). Aims: Our aims are to identify and describe the population that revisits the ED for SA/SH, and to determine the factors that influence revisit rates. Methods: This retrospective study was conducted from August 2022 to April 2024, reviewing ED visits from January 2019 to December 2021 at a single center. Data on demographics, diagnoses, family history, stressors, and outpatient care were analyzed. Statistical analyses, including Kruskal-Wallis, Mann-Whitney U, and correlation, were conducted. Results: Among 138 participants (mean age 34.47 years), 83 (60.14%) were female, 86 (62.32%) were White, and 77 (55.80%) were on Medicaid. Psychiatric illness was present in 118 (85.51%), with depressive disorders most common, 76 (64.41%). Almost half of participants, 64 (46.38%), had a family psychiatric history, 28 (20.29%) participants had a diagnosis of hypertension and they had a significantly higher average revisit rate (p = 0.049), and 64 (46.38%) participants used a substance during SA/SH, with alcohol being the most frequently used. Oral medication was the most common method for SA, 145 (54.92% of SAs). Prior to the study period, 43 participants (31.16%) had seen a PCP, and only 70 ED visits (20.23%) resulted in scheduled outpatient follow-up. No significant differences were found between revisits and sex, age, payer status, or income (P > 0.05). Conclusions: Our study demonstrated that psychiatric illness, substance use, and a family history of psychiatric disorders were highly prevalent among individuals with repeat ED visits for SA/SH. We propose that improving scheduled follow-up care after an event, encouraging PCP suicide-risk assessment, and medication management could serve as key intervention areas to reduce reattempts. Future research should focus on targeted interventions for high-risk populations, such as those with chronic diseases such as hypertension.
- 16 October 2025
- Published by Springer Nature in Cureus
- Vol. 17  (10) , e94712
Open AccessDemographic, Socioeconomic, and Clinical Determinants of Repeat Suicide Attempts: A Retrospective Study of Emergency Department Visits at a Community Hospital
Background: Suicide is a critical public health issue in the United States, yet research is lacking on understanding the population that visits the Emergency Department (ED) for repeated suicide attempts (SA) and self-harm (SH). Aims: Our aims are to identify and describe the population that revisits the ED for SA/SH, and to determine the factors that influence revisit rates. Methods: This retrospective study was conducted from August 2022 to April 2024, reviewing ED visits from January 2019 to December 2021 at a single center. Data on demographics, diagnoses, family history, stressors, and outpatient care were analyzed. Statistical analyses, including Kruskal-Wallis, Mann-Whitney U, and correlation, were conducted. Results: Among 138 participants (mean age 34.47 years), 83 (60.14%) were female, 86 (62.32%) were White, and 77 (55.80%) were on Medicaid. Psychiatric illness was present in 118 (85.51%), with depressive disorders most common, 76 (64.41%). Almost half of participants, 64 (46.38%), had a family psychiatric history, 28 (20.29%) participants had a diagnosis of hypertension and they had a significantly higher average revisit rate (p = 0.049), and 64 (46.38%) participants used a substance during SA/SH, with alcohol being the most frequently used. Oral medication was the most common method for SA, 145 (54.92% of SAs). Prior to the study period, 43 participants (31.16%) had seen a PCP, and only 70 ED visits (20.23%) resulted in scheduled outpatient follow-up. No significant differences were found between revisits and sex, age, payer status, or income (P > 0.05). Conclusions: Our study demonstrated that psychiatric illness, substance use, and a family history of psychiatric disorders were highly prevalent among individuals with repeat ED visits for SA/SH. We propose that improving scheduled follow-up care after an event, encouraging PCP suicide-risk assessment, and medication management could serve as key intervention areas to reduce reattempts. Future research should focus on targeted interventions for high-risk populations, such as those with chronic diseases such as hypertension.
- Open Access
- 9 September 2025
- Published by Springer Nature in Cureus
- Vol. 17  (9) , e91886
From Rights to Risks: Mental Health Implications for Pregnant Patients Following the Reversal of Roe v. Wade
Introduction The overturn of Roe v. Wade threatened reproductive rights, leading to bans, delayed access to care, and potentially increased psychological stress surrounding abortion care. We aim to assess the incidence and prevalence of acute stress episodes (ASE) and depressive episode diagnoses in patients after a non-spontaneous abortion. Methods We used a medical record database, TriNetX (TriNetX, LLC, Cambridge, MA), to assess the incidence and prevalence of depressive episodes (International Classification of Diseases, Tenth Revision, Clinical Modification {ICD-10-CM}=F32) and acute stress episodes (ICD-10-CM=F43.0, F43.9, and F43.11) in patients who received non-spontaneous abortions across 66 US healthcare organizations. We used relative risk with 95% confidence intervals to compare outcomes across three periods: pre-COVID (July 2017-2019), COVID (July 2020-2022), and post-Roe v. Wade (pRvW, July 2022-2024). Chi-squared (Ï2) tests assessed differences within racial groups from 2017 to 2024. Results The prevalence of acute psychiatric episodes increased over time (depressive episodes: pre-COVID/COVID=0.779 {0.766-0.791} and COVID/pRvW=0.794 {0.783-0.806}; acute stress episode: pre-COVID/COVID=0.745 {0.713-0.779} and COVID/pRvW=0.739 {0.710-0.770}). The incidence of depressive episodes dipped during COVID and was highest during pRvW (pre-COVID/COVID, 1.062 {1.010-1.117}; COVID/pRvW, 0.845 {0.802-0.890}; pre-COVID/pRvW, 0.897 {0.850-0.947}). The incidence of acute stress episodes increased in the COVID and pRvW periods, but these periods were not statistically different from each other (pre-COVID/COVID, 0.838 {0.741-0.947}; pre-COVID/pRvW, 0.759 {0.667-0.863}). The prevalence of depressive episodes increased significantly for African American patients (Ï2=15.845, degrees of freedom {dF}=6, and p=0.0146). Discussion Overall, there has been an increase in the incidence and prevalence of acute stress episode and depressive episode diagnoses since the overturn of Roe v. Wade, with certain racial groups being disproportionately impacted. This illustrates the need for improved psychological resources, specifically for marginalized communities. Conclusion The overturn of Roe v. Wade seems to be associated with an increased incidence and prevalence of acute psychiatric diagnoses after a non-spontaneous abortion. Further studies should be conducted to establish such an association.
- 9 September 2025
- Published by Springer Nature in Cureus
- Vol. 17  (9) , e91886
Open AccessFrom Rights to Risks: Mental Health Implications for Pregnant Patients Following the Reversal of Roe v. Wade
Introduction The overturn of Roe v. Wade threatened reproductive rights, leading to bans, delayed access to care, and potentially increased psychological stress surrounding abortion care. We aim to assess the incidence and prevalence of acute stress episodes (ASE) and depressive episode diagnoses in patients after a non-spontaneous abortion. Methods We used a medical record database, TriNetX (TriNetX, LLC, Cambridge, MA), to assess the incidence and prevalence of depressive episodes (International Classification of Diseases, Tenth Revision, Clinical Modification {ICD-10-CM}=F32) and acute stress episodes (ICD-10-CM=F43.0, F43.9, and F43.11) in patients who received non-spontaneous abortions across 66 US healthcare organizations. We used relative risk with 95% confidence intervals to compare outcomes across three periods: pre-COVID (July 2017-2019), COVID (July 2020-2022), and post-Roe v. Wade (pRvW, July 2022-2024). Chi-squared (Ï2) tests assessed differences within racial groups from 2017 to 2024. Results The prevalence of acute psychiatric episodes increased over time (depressive episodes: pre-COVID/COVID=0.779 {0.766-0.791} and COVID/pRvW=0.794 {0.783-0.806}; acute stress episode: pre-COVID/COVID=0.745 {0.713-0.779} and COVID/pRvW=0.739 {0.710-0.770}). The incidence of depressive episodes dipped during COVID and was highest during pRvW (pre-COVID/COVID, 1.062 {1.010-1.117}; COVID/pRvW, 0.845 {0.802-0.890}; pre-COVID/pRvW, 0.897 {0.850-0.947}). The incidence of acute stress episodes increased in the COVID and pRvW periods, but these periods were not statistically different from each other (pre-COVID/COVID, 0.838 {0.741-0.947}; pre-COVID/pRvW, 0.759 {0.667-0.863}). The prevalence of depressive episodes increased significantly for African American patients (Ï2=15.845, degrees of freedom {dF}=6, and p=0.0146). Discussion Overall, there has been an increase in the incidence and prevalence of acute stress episode and depressive episode diagnoses since the overturn of Roe v. Wade, with certain racial groups being disproportionately impacted. This illustrates the need for improved psychological resources, specifically for marginalized communities. Conclusion The overturn of Roe v. Wade seems to be associated with an increased incidence and prevalence of acute psychiatric diagnoses after a non-spontaneous abortion. Further studies should be conducted to establish such an association.
- Open Access
- 18 August 2025
- Published by Springer Nature in Cureus
- Vol. 17  (8)
Association Between Stimulant Medication Use in Attention-Deficit/Hyperactivity Disorder (ADHD) and the Increased Risk of Upper Respiratory Tract Infections: A Retrospective Study
Introduction Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental condition that can persist from childhood into adulthood. Stimulant medications such as methylphenidate and amphetamine derivatives are the mainstay of treatment, yet their potential immunomodulatory effects remain unclear. While most upper respiratory tract infections (URTIs) are benign and self-limiting, some may result in healthcare visits and lost productivity. Proposed mechanisms linking stimulant use to infection risk include sympathetic nervous system activation, hypothalamic-pituitary-adrenal axis modulation, stimulant-induced insomnia, and reduced salivary flow - all of which may impair mucosal immunity. This study aimed to evaluate whether stimulant medication use in ADHD is associated with increased risk of URTIs using a large real-world dataset. Methods We performed a retrospective cohort study using the TriNetX research network, which aggregates de-identified electronic health records from 149 healthcare organizations worldwide (>170 million patients). ADHD patients were identified by International Classification of Diseases, 10th Revision (ICD-10) codes F90.0-F90.2. Two cohorts were defined: ADHD patients without stimulant prescriptions (control; n = 1,798,001) and ADHD patients prescribed stimulants (medication cohort; n = 1,099,756; amphetamine, dextroamphetamine, lisdexamfetamine, methylphenidate, modafinil, or dexmethylphenidate). We did not include antidepressants and antipsychotics in the cohorts or in their comparison. The outcome was a diagnosis of URTI (ICD-10 J00-J06). Risk estimates, Kaplan-Meier survival analysis, log-rank test, and Cox proportional hazards modeling were performed within TriNetX, with significance set at p < 0.05. Results A total of 2,897,757 ADHD patients were included (mean age 21.2 ± 15 years; 42.1% female). URTI incidence was higher in the medication cohort (31.2%, n = 343,385) than in controls (28.5%, n = 512,849). Stimulant exposure was associated with increased URTI risk: risk difference 0.027 (95% confidence interval (CI): 0.026-0.028; p < 0.001), risk ratio 1.095 (95% CI: 1.091-1.099), and odds ratio 1.138 (95% CI: 1.132-1.144). Kaplan-Meier analysis demonstrated significantly lower URTI-free survival in medicated patients (log-rank ÏÂČ = 2285.0; p < 0.001). The hazard ratio for URTI in the medicated cohort was 1.111 (95% CI: 1.106-1.116; p < 0.001). Median survival without URTI was 3757 days in controls versus 3176 days in the medicated group. Discussion Stimulant-treated ADHD patients exhibited an 11% higher relative risk of URTI compared with unmedicated patients. Some possible mechanisms may include immune suppression via catecholamine-mediated shifts in cytokine profiles, sleep disruption leading to impaired host defenses, and medication-induced xerostomia, reducing mucosal protection. Our findings align with prior clinical and epidemiologic studies reporting higher infection rates in ADHD populations, although prior results have been mixed. Conclusion In this large multi-institutional analysis, stimulant use in ADHD was moderately associated with increased URTI risk. These findings warrant consideration in risk-benefit discussions for ADHD treatment, particularly for patients with frequent infections or compromised immunity. Future prospective studies should explore dose-response effects, adherence, and biologic mediators to clarify causality and guide preventive strategies.
- 18 August 2025
- Published by Springer Nature in Cureus
- Vol. 17  (8)
Open AccessAssociation Between Stimulant Medication Use in Attention-Deficit/Hyperactivity Disorder (ADHD) and the Increased Risk of Upper Respiratory Tract Infections: A Retrospective Study
Introduction Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental condition that can persist from childhood into adulthood. Stimulant medications such as methylphenidate and amphetamine derivatives are the mainstay of treatment, yet their potential immunomodulatory effects remain unclear. While most upper respiratory tract infections (URTIs) are benign and self-limiting, some may result in healthcare visits and lost productivity. Proposed mechanisms linking stimulant use to infection risk include sympathetic nervous system activation, hypothalamic-pituitary-adrenal axis modulation, stimulant-induced insomnia, and reduced salivary flow - all of which may impair mucosal immunity. This study aimed to evaluate whether stimulant medication use in ADHD is associated with increased risk of URTIs using a large real-world dataset. Methods We performed a retrospective cohort study using the TriNetX research network, which aggregates de-identified electronic health records from 149 healthcare organizations worldwide (>170 million patients). ADHD patients were identified by International Classification of Diseases, 10th Revision (ICD-10) codes F90.0-F90.2. Two cohorts were defined: ADHD patients without stimulant prescriptions (control; n = 1,798,001) and ADHD patients prescribed stimulants (medication cohort; n = 1,099,756; amphetamine, dextroamphetamine, lisdexamfetamine, methylphenidate, modafinil, or dexmethylphenidate). We did not include antidepressants and antipsychotics in the cohorts or in their comparison. The outcome was a diagnosis of URTI (ICD-10 J00-J06). Risk estimates, Kaplan-Meier survival analysis, log-rank test, and Cox proportional hazards modeling were performed within TriNetX, with significance set at p < 0.05. Results A total of 2,897,757 ADHD patients were included (mean age 21.2 ± 15 years; 42.1% female). URTI incidence was higher in the medication cohort (31.2%, n = 343,385) than in controls (28.5%, n = 512,849). Stimulant exposure was associated with increased URTI risk: risk difference 0.027 (95% confidence interval (CI): 0.026-0.028; p < 0.001), risk ratio 1.095 (95% CI: 1.091-1.099), and odds ratio 1.138 (95% CI: 1.132-1.144). Kaplan-Meier analysis demonstrated significantly lower URTI-free survival in medicated patients (log-rank ÏÂČ = 2285.0; p < 0.001). The hazard ratio for URTI in the medicated cohort was 1.111 (95% CI: 1.106-1.116; p < 0.001). Median survival without URTI was 3757 days in controls versus 3176 days in the medicated group. Discussion Stimulant-treated ADHD patients exhibited an 11% higher relative risk of URTI compared with unmedicated patients. Some possible mechanisms may include immune suppression via catecholamine-mediated shifts in cytokine profiles, sleep disruption leading to impaired host defenses, and medication-induced xerostomia, reducing mucosal protection. Our findings align with prior clinical and epidemiologic studies reporting higher infection rates in ADHD populations, although prior results have been mixed. Conclusion In this large multi-institutional analysis, stimulant use in ADHD was moderately associated with increased URTI risk. These findings warrant consideration in risk-benefit discussions for ADHD treatment, particularly for patients with frequent infections or compromised immunity. Future prospective studies should explore dose-response effects, adherence, and biologic mediators to clarify causality and guide preventive strategies.
- Open Access
- 25 February 2025
- Published by Springer Nature in Cureus
- Vol. 17  (2) , e79616
The Long-Term Impact of Lorazepam on Catatonia Recurrence in Patients With Bipolar Disorder
Introduction: Catatonia is a complex syndrome characterized by behavioral and psychomotor abnormalities and is commonly associated with various medical and psychiatric conditions including schizophrenia, bipolar disorder, depression, stroke, and encephalitis. Lorazepam is widely considered the first-line treatment for catatonia, but the drugâs effectiveness in preventing recurrence remains unclear. This study examines whether lorazepam reduces the risk of recurrent catatonia in patients with bipolar disorder. Methods: We conducted a retrospective cohort study using the TriNetX database, including patients who were diagnosed with bipolar disorder and catatonia between 2000 and 2024. Patients were divided into two groups: those treated with lorazepam (n = 15,674) and those who did not receive lorazepam (n = 12,045). Kaplan-Meier survival analysis and hazard ratios were used to assess recurrence risk and long-term outcomes. Results: Overall, the catatonia recurrence rate was similar between groups (p = 0.086). However, the group that did not receive lorazepam had a statistically significantly fewer total number of recurrent episodes of catatonia than the lorazepam treatment group (p = 0.005). Additionally, Kaplan-Meier analysis showed a significantly higher survival probability in the no lorazepam group (p = 0.011), indicating a longer duration of time before recurrence in this cohort. Conclusion: Lorazepam effectively treats catatonia acutely but does not significantly reduce the risk of recurrence compared to other management options. Future studies should explore individualized treatment approaches to optimize catatonia management for patients with bipolar disorder.
- 25 February 2025
- Published by Springer Nature in Cureus
- Vol. 17  (2) , e79616
Open AccessThe Long-Term Impact of Lorazepam on Catatonia Recurrence in Patients With Bipolar Disorder
Introduction: Catatonia is a complex syndrome characterized by behavioral and psychomotor abnormalities and is commonly associated with various medical and psychiatric conditions including schizophrenia, bipolar disorder, depression, stroke, and encephalitis. Lorazepam is widely considered the first-line treatment for catatonia, but the drugâs effectiveness in preventing recurrence remains unclear. This study examines whether lorazepam reduces the risk of recurrent catatonia in patients with bipolar disorder. Methods: We conducted a retrospective cohort study using the TriNetX database, including patients who were diagnosed with bipolar disorder and catatonia between 2000 and 2024. Patients were divided into two groups: those treated with lorazepam (n = 15,674) and those who did not receive lorazepam (n = 12,045). Kaplan-Meier survival analysis and hazard ratios were used to assess recurrence risk and long-term outcomes. Results: Overall, the catatonia recurrence rate was similar between groups (p = 0.086). However, the group that did not receive lorazepam had a statistically significantly fewer total number of recurrent episodes of catatonia than the lorazepam treatment group (p = 0.005). Additionally, Kaplan-Meier analysis showed a significantly higher survival probability in the no lorazepam group (p = 0.011), indicating a longer duration of time before recurrence in this cohort. Conclusion: Lorazepam effectively treats catatonia acutely but does not significantly reduce the risk of recurrence compared to other management options. Future studies should explore individualized treatment approaches to optimize catatonia management for patients with bipolar disorder.
- Open Access
- 14 February 2025
- Published by Springer Nature in Cureus
- Vol. 17  (2) , e78995
Methylphenidate-Induced Dyskinesia in a 47-Year-Old Female With Acute Lymphoblastic Leukemia
Dyskinesia describes a broad category of involuntary body movements. The presentation of dyskinesia is variable, ranging from quick jerking and twitching to smooth âdance-likeâ movements. Dyskinesia can occur in the extremities, face, or trunk. They can result from the use of certain medications and various medical conditions. One cause, explored in this paper, is dyskinesia as a side effect of methylphenidate use. We report on a 47-year-old woman with a past medical history of hypoplastic low-grade myelodysplastic syndrome with pancytopenia, acute lymphoblastic leukemia (in remission), and generalized fatigue treated with methylphenidate for her fatigue and decreased concentration. The patient presented from home to the emergency department with expressive aphasia, facial spasming, and involuntary extremity movement. Initial concern for stroke was ruled out and ultimately methylphenidate was determined to be the offending agent. Although our case focuses on an adult, cancer patient affected by dyskinesia following methylphenidate use, dyskinesia is a reported side effect with methylphenidate use in other populations. Clinicians should be aware of this association because of methylphenidateâs extensive use in the treatment of attention deficit hyperactivity disorder (ADHD) and its increasing use in other patient populations, like cancer patients and patients with brain injuries.
- 14 February 2025
- Published by Springer Nature in Cureus
- Vol. 17  (2) , e78995
Open AccessMethylphenidate-Induced Dyskinesia in a 47-Year-Old Female With Acute Lymphoblastic Leukemia
Dyskinesia describes a broad category of involuntary body movements. The presentation of dyskinesia is variable, ranging from quick jerking and twitching to smooth âdance-likeâ movements. Dyskinesia can occur in the extremities, face, or trunk. They can result from the use of certain medications and various medical conditions. One cause, explored in this paper, is dyskinesia as a side effect of methylphenidate use. We report on a 47-year-old woman with a past medical history of hypoplastic low-grade myelodysplastic syndrome with pancytopenia, acute lymphoblastic leukemia (in remission), and generalized fatigue treated with methylphenidate for her fatigue and decreased concentration. The patient presented from home to the emergency department with expressive aphasia, facial spasming, and involuntary extremity movement. Initial concern for stroke was ruled out and ultimately methylphenidate was determined to be the offending agent. Although our case focuses on an adult, cancer patient affected by dyskinesia following methylphenidate use, dyskinesia is a reported side effect with methylphenidate use in other populations. Clinicians should be aware of this association because of methylphenidateâs extensive use in the treatment of attention deficit hyperactivity disorder (ADHD) and its increasing use in other patient populations, like cancer patients and patients with brain injuries.
- Open Access
- 28 January 2025
- Published by Springer Nature in Cureus
- Vol. 17  (1) , e78116
Pseudobulbar Affect Among Patients With Dementia
Objective: Dementia is a neurocognitive disorder characterized by memory loss and deficits in multiple cognitive domains, caused by damage to or loss of neurons in the brain, which impairs oneâs abilities and capabilities for independent daily living. The etiologies of dementia are diverse, including vascular, infectious, traumatic, and neurodegenerative causes. The most common types of dementia include Alzheimerâs dementia, vascular dementia, Lewy body dementia, and frontotemporal dementia. Patients with dementia frequently develop cognitive, psycho-behavioral, emotional, and mood symptoms. One largely unstudied mood symptom seen in dementia patients is pseudobulbar affect (PBA). PBA is a state of emotional incontinence characterized by episodes of uncontrolled crying or laughter that are inconsistent with the social context or the patientâs emotional state. Although many neurological disorders may present with PBA, only a small fraction of the literature focuses on PBA in dementia patients. In the present study, we used the TriNetX database to identify a cohort of patients with both PBA and dementia. We describe this cohort to provide a foundation for further research on this patient population. Results: Seventy-three percent (n=182) of the cohort had postconcussion syndrome, 18% (n=44) had overt dementia, 49% (n=121) had mild cognitive impairment, and 42% (n=105) had some form of amnesia. Many patients had comorbid psychiatric disorders, including anxiety and depressive disorders. Conclusions: The multitude of comorbid mood disorders and symptoms can complicate the clinical management of dementia patients, adding to their distress and that of their caregivers. Understanding these symptoms is essential for providing an accurate diagnosis and effective management of PBA in dementia.
- 28 January 2025
- Published by Springer Nature in Cureus
- Vol. 17  (1) , e78116
Open AccessPseudobulbar Affect Among Patients With Dementia
Objective: Dementia is a neurocognitive disorder characterized by memory loss and deficits in multiple cognitive domains, caused by damage to or loss of neurons in the brain, which impairs oneâs abilities and capabilities for independent daily living. The etiologies of dementia are diverse, including vascular, infectious, traumatic, and neurodegenerative causes. The most common types of dementia include Alzheimerâs dementia, vascular dementia, Lewy body dementia, and frontotemporal dementia. Patients with dementia frequently develop cognitive, psycho-behavioral, emotional, and mood symptoms. One largely unstudied mood symptom seen in dementia patients is pseudobulbar affect (PBA). PBA is a state of emotional incontinence characterized by episodes of uncontrolled crying or laughter that are inconsistent with the social context or the patientâs emotional state. Although many neurological disorders may present with PBA, only a small fraction of the literature focuses on PBA in dementia patients. In the present study, we used the TriNetX database to identify a cohort of patients with both PBA and dementia. We describe this cohort to provide a foundation for further research on this patient population. Results: Seventy-three percent (n=182) of the cohort had postconcussion syndrome, 18% (n=44) had overt dementia, 49% (n=121) had mild cognitive impairment, and 42% (n=105) had some form of amnesia. Many patients had comorbid psychiatric disorders, including anxiety and depressive disorders. Conclusions: The multitude of comorbid mood disorders and symptoms can complicate the clinical management of dementia patients, adding to their distress and that of their caregivers. Understanding these symptoms is essential for providing an accurate diagnosis and effective management of PBA in dementia.
- Open Access
- 29 November 2024
- Published by Springer Nature in Cureus
- Vol. 16  (11) , e74761
Haloperidol-Induced Laryngeal Dystonia: A Case Report on an Antipsychotic-Associated Airway Emergency
Acute dystonia is a neurological condition characterized by involuntary muscle contractions that can affect various parts of the body. It is commonly triggered by the use of antipsychotic medications, especially within the first few days after administration. Respiratory acute laryngeal dystonia, a particularly severe form of this condition and a very subtype of laryngeal dystonia, can lead to respiratory distress and airway obstruction if not promptly treated. This case report describes a 23-year-old male who developed acute laryngeal dystonia within 24 hours of receiving haloperidol for agitation. The patient presented with hoarseness, difficulty swallowing, and progressive respiratory distress, eventually requiring emergent intubation due to airway compromise. This case underscores the need for healthcare providers to recognize and promptly manage rare but potentially life-threatening side effects of antipsychotic medications. Particular attention must be directed toward patients with risk factors for developing extrapyramidal reactions. Early intervention is crucial to prevent progression to airway obstruction and respiratory failure.
- 29 November 2024
- Published by Springer Nature in Cureus
- Vol. 16  (11) , e74761
Open AccessHaloperidol-Induced Laryngeal Dystonia: A Case Report on an Antipsychotic-Associated Airway Emergency
Acute dystonia is a neurological condition characterized by involuntary muscle contractions that can affect various parts of the body. It is commonly triggered by the use of antipsychotic medications, especially within the first few days after administration. Respiratory acute laryngeal dystonia, a particularly severe form of this condition and a very subtype of laryngeal dystonia, can lead to respiratory distress and airway obstruction if not promptly treated. This case report describes a 23-year-old male who developed acute laryngeal dystonia within 24 hours of receiving haloperidol for agitation. The patient presented with hoarseness, difficulty swallowing, and progressive respiratory distress, eventually requiring emergent intubation due to airway compromise. This case underscores the need for healthcare providers to recognize and promptly manage rare but potentially life-threatening side effects of antipsychotic medications. Particular attention must be directed toward patients with risk factors for developing extrapyramidal reactions. Early intervention is crucial to prevent progression to airway obstruction and respiratory failure.
- Open Access
- 1 October 2024
- Published by Springer Nature in Cureus
- Vol. 16  (10) , e70585
Psychosis to Pancreatitis: A Case Study Exploring the Risks of Hypertriglyceridemia in a Patient Treated With Olanzapine
Olanzapine is an antipsychotic medication that is used in the management of schizophrenia and bipolar disorder, but it is not without any adverse effects. We present the following case of a 24-year-old man with a history of schizoaffective disorder, obesity, and anxiety, who developed hypertriglyceridemia-induced acute pancreatitis after six months on olanzapine. Despite his adherence to the medication, routine metabolic monitoring was not performed leading to a delayed diagnosis of hypertriglyceridemia and subsequent complications. The case underscores the critical need for regular metabolic monitoring in patients prescribed olanzapine to prevent severe adverse effects and guide timely intervention. Enhanced adherence to monitoring guidelines and consideration of alternative treatments may help mitigate such risks.
- 1 October 2024
- Published by Springer Nature in Cureus
- Vol. 16  (10) , e70585
Open AccessPsychosis to Pancreatitis: A Case Study Exploring the Risks of Hypertriglyceridemia in a Patient Treated With Olanzapine
Olanzapine is an antipsychotic medication that is used in the management of schizophrenia and bipolar disorder, but it is not without any adverse effects. We present the following case of a 24-year-old man with a history of schizoaffective disorder, obesity, and anxiety, who developed hypertriglyceridemia-induced acute pancreatitis after six months on olanzapine. Despite his adherence to the medication, routine metabolic monitoring was not performed leading to a delayed diagnosis of hypertriglyceridemia and subsequent complications. The case underscores the critical need for regular metabolic monitoring in patients prescribed olanzapine to prevent severe adverse effects and guide timely intervention. Enhanced adherence to monitoring guidelines and consideration of alternative treatments may help mitigate such risks.
- Open Access
- 2 September 2024
- Published by Springer Nature in Cureus
- Vol. 16  (9) , e68450
Substance Use Disorder as a Risk Factor for Postpartum Depression: A Retrospective Chart Review in a Community Hospital
Objective: This retrospective study examines the relationship between postpartum depression (PPD) and substance use disorder (SUD) in a community hospital setting. Methods: This retrospective chart review explored the association between SUD and PPD in a community hospital. Data from January 2016 to December 2018 were extracted from electronic medical records (EPIC EMR (Epic Systems Corporation, Verona, WI)), identifying mothers with PPD (n = 99) using billing code F53.0. Substance use disorder was assessed using diagnostic codes F10-F19. Odds ratios (OR), relative risk (RR), and chi-square tests were calculated to quantify and assess the significance of the association between SUD and PPD. Ethical approval was obtained from the Institutional Review Board (IRB). Results: Among 2,517 deliveries during the study period, 51 cases of PPD co-occurred with SUD. Mothers with SUD had a 4.3 times higher risk of PPD compared to those without SUD (OR = 4.8), highlighting a significant association. Discussion: These findings emphasize the importance of screening for PPD and SUD in pregnant and postpartum women, especially in community healthcare settings where routine screening may be limited. Targeted interventions can mitigate adverse effects on maternal and infant well-being.
- 2 September 2024
- Published by Springer Nature in Cureus
- Vol. 16  (9) , e68450
Open AccessSubstance Use Disorder as a Risk Factor for Postpartum Depression: A Retrospective Chart Review in a Community Hospital
Objective: This retrospective study examines the relationship between postpartum depression (PPD) and substance use disorder (SUD) in a community hospital setting. Methods: This retrospective chart review explored the association between SUD and PPD in a community hospital. Data from January 2016 to December 2018 were extracted from electronic medical records (EPIC EMR (Epic Systems Corporation, Verona, WI)), identifying mothers with PPD (n = 99) using billing code F53.0. Substance use disorder was assessed using diagnostic codes F10-F19. Odds ratios (OR), relative risk (RR), and chi-square tests were calculated to quantify and assess the significance of the association between SUD and PPD. Ethical approval was obtained from the Institutional Review Board (IRB). Results: Among 2,517 deliveries during the study period, 51 cases of PPD co-occurred with SUD. Mothers with SUD had a 4.3 times higher risk of PPD compared to those without SUD (OR = 4.8), highlighting a significant association. Discussion: These findings emphasize the importance of screening for PPD and SUD in pregnant and postpartum women, especially in community healthcare settings where routine screening may be limited. Targeted interventions can mitigate adverse effects on maternal and infant well-being.